A conjugate of the lytic peptide Hecate (bee venom analog) with FSH fragments selectively destroys cancer cells that express FSH receptors while sparing receptor-negative cells.
Selective killHecate-FSH beta conjugate destroyed FSHR-positive cancer cells while sparing FSHR-negative cells
What the researchers found
Hecate-FSH beta 33-53 C/S conjugate selectively killed FSHR-positive cancer cells (KGN granulosa tumor cells and FSHR-transfected HEK293 cells) while showing minimal toxicity to FSHR-negative controls.
Why it matters
Selective cancer cell killing without harming normal tissue is the holy grail of cancer therapy; this peptide conjugate achieves receptor-targeted cytotoxicity using a nature-derived lytic peptide.
The numbers in context
Tested in KGN granulosa tumor cells, HEK293-FSHR cells, and FSHR-negative controls; C/S variant showed highest specific cytotoxicity.
How the study worked
In vitro cytotoxicity testing of Hecate-FSH beta conjugate variants in FSHR-positive (KGN, HEK293-FSHR) and FSHR-negative (mock-transfected HEK293) cell lines.
Who was studied
N/A (cancer cell lines)
What this study cannot tell us
In vitro study only — in vivo tumor targeting, biodistribution, stability, and safety not yet assessed; FSHR expression varies across tumor types and patients.
How to read the evidence
In vitro proof-of-concept study; demonstrates selectivity but animal and human studies are needed.
When this study was published
Published in 2025, contributing to the growing field of targeted lytic peptide cancer therapeutics.
The bigger picture
Peptide-based targeted cancer therapies are gaining traction as alternatives to antibody-drug conjugates, offering advantages in size, tissue penetration, and manufacturing simplicity.
Questions still open
- Can this Hecate-FSH beta conjugate effectively target FSHR-positive tumors in vivo without off-target toxicity to ovarian tissue?
- Could this approach be combined with other peptide-drug conjugate strategies for enhanced efficacy?
Common questions
How does this peptide target cancer cells?
What types of cancer express FSH receptors?
Read the original research
Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kills targeted follicle stimulating hormone receptor (FSHR)-positive cancer cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 186, 118022
Citation
Rahman, Nafis A; Chrusciel, Marcin; Ponikwicka-Tyszko, Donata; Pulawska-Moon, Kamila; Stelmaszewska, Joanna; Doroszko, Milena; Kreuzer, Oliver J; Rivero-Muller, Adolfo; Li, Xiangdong; Ziecik, Adam J; Wolczynski, Slawomir; Huhtaniemi, Ilpo. (2025). Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kills targeted follicle stimulating hormone receptor (FSHR)-positive cancer cells.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 186, 118022. https://doi.org/10.1016/j.biopha.2025.118022